Cipla on USFDA radar, stock goes down

By Vivek Iyer

Cipla is on the USFDA radar as the regulator is carrying out a surprise inspection at its Goa facility, said sources.

Three USFDA auditors are believed to have started the inspection at the Goa plant on monday.

The Goa facility accounts for as much as 20-25 per cent of the drugmaker's US revenues. Analysts say the plant constitutes a significant link as far as the ANDA pipeline is concerned.

“Cipla confirms the commencement of a routine Current Good Manufacturing Practice (CGMP) and pre-approval inspection (PAI) at its Goa facility,” the spokesperson of the pharma major said.

The stock was down more than half a per cent on the BSE in afternoon trade on monday.